Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

In R&D developments, the company had several significant obesity treatment readouts, including CagriSema, semaglutide 7.2 milligram, and amycretin. Looking ahead to 2025, Novo Nordisk A/S (NYSE ...

The company is also developing the oral amycretin. Novo will have a nice heads up on the manufacturing challenge because it already markets Rybelsus, which became the first oral treatment for type 2 ...

The company completed the acquisition of the 3 Catalent sites, and during FY 2024, it progressed its R&D pipeline, including obesity projects like CagriSema and amycretin. In 2025, Novo Nordisk A ...

In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in body weight of approximately 2% in those treated with ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...